[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533930":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":19,"locations":25,"responsibleParty":71,"collaborators":18,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":18,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":27,"whyStopped":18,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Neuropsychological assessment","Determination of the neuropsychological profile",[12],"Other: Patients suffering from the co-occurrence of ADHD and addiction(s)",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":18},"Patients suffering from the co-occurrence of ADHD and addiction(s)","All eligible patients over 18 years, presenting both a diagnosis of ADHD and a diagnosis of at least one addictive disorder (SUD, AUD (Alcohol Use Disorder) and\u002F or behavioral addiction), starting care in one of the three participating centers, and meeting the indication for treatment with MPH according to European recommendations (J. J. S. Kooij et al., 2019)",[9],null,[20],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Clémence CABELGUEN, PH","CONTACT","33 2 40 84 61 16","clemence.cabelguen@chu-nantes.fr",[26,45,58],{"facility":5,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Nantes","Loire-Atlantique","44093","France","FR",{"type":34,"coordinates":35},"Point",[36,37],-1.55336,47.21725,{"lat":37,"lon":36},[40,41],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},{"name":42,"role":22,"phone":43,"phoneExt":18,"email":44},"Gaelle CHALLET","33 2 53 48 25 32","gaelle.challet@chu-nantes.fr",{"facility":46,"status":27,"city":47,"state":18,"zip":48,"country":31,"countryCode":32,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"CHRU de Brest","Brest","29000",{"type":34,"coordinates":50},[51,52],-4.48628,48.39029,{"lat":52,"lon":51},[55],{"name":56,"role":22,"phone":18,"phoneExt":18,"email":57},"Morgane Guillou-Landreat, PH","morgane.guillou@chu-brest.fr",{"facility":59,"status":27,"city":60,"state":18,"zip":61,"country":31,"countryCode":32,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"CHRU de Tours","Tours","37000",{"type":34,"coordinates":63},[64,65],0.70398,47.39484,{"lat":65,"lon":64},[68],{"name":69,"role":22,"phone":18,"phoneExt":18,"email":70},"Paul Brunault, PH","paul.brunault@univ-tours.fr",{"type":72,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100533930","attention-deficit-hyperactivity-disorder-100533930",false,"NCT06232226","Attention Deficit Hyperactivity Disorder","Addictions and Attention Deficit Disorder With or Without Hyperactivity","ADA","Inclusion Criteria :\n\n* Patients aged over 18 years\n* For whom a diagnosis of ADHD has been confirmed less than 12 weeks ago\n* For whom the diagnosis of one or more addictive disorder(s) (substance use disorder or behavioral addiction) has been confirmed\n* Meeting the indication for treatment with MPH according to European recommendations (Kooij et al., 2019)\n* For patients who can actually benefit from MPH: who have not yet started taking MPH\n* Social security affiliates\n\nExclusion Criteria :\n\n* Presenting disorders of higher cognitive functions (at the discretion of the referring clinician or the investigator making the inclusion), making data collection impossible\n* Presenting difficulties in reading or writing the French language making data collection impossible\n* Unable to commit to being available for the 2 visits planned as part of the cohort\n* Under guardianship or legal protection\n* Patients who have used psychoactive substances within 12 hours prior to their visit","ALL","18 Years","99 Years",{"count":85,"type":86},80,"ESTIMATED","INTERVENTIONAL",[89],"NA","The ADA cohort aims for the systematic and standardized collection of sociodemographic, clinical and neuropsychological data, during 2 visits (inclusion and 12 months), from patients suffering from the co-occurrence of ADHD (Attention Deficit Hyperactivity Disorder) and addiction(s), in addition to the treatment as usual adapted to each situation.",[77,92,93],"Behavior Hyperactive","Behavior Disorders",[95,96,97,98,99,100,101],"Attention Deficit Disorder with Hyperactivity","Addictive disorders","Neuropsychology","Methylphenidate","Atomoxetine","Functional impairment","Symptoms","2026-04-14",{"date":104,"type":105},"2026-04-17","ACTUAL",{"date":107,"type":105},"2024-04-11",{"date":109,"type":86},"2026-12-31",{"name":5,"class":6},3]